Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | PLG | P00747 | 1/20 | 0.43 |
| ▸ | PLAT | P00750 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | GABRP | O00591 | 1/20 | 0.42 |
| ▸ | GABRD | O14764 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.42 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.42 |
| ▸ | GABRE | P78334 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.42 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.42 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21542410 | 1.00 | LMNA (0.43) | LMNAPLGPLATTSHRGABRP | |
| SCHEMBL20293395 | 1.00 | LMNA (0.43) | LMNAPLGPLATTSHRGABRP | |
| Cyclopropane Carboxylic Acid SCHEMBL27700167 | 0.81 | — | — | |
| SCHEMBL7882902 | 0.81 | LMNA (0.40) | LMNAPLGPLATTSHRGABRP | |
| SCHEMBL7882901 | 0.81 | LMNA (0.40) | LMNAPLGPLATTSHRGABRP | |
| SCHEMBL7888314 | 0.81 | LMNA (0.40) | LMNAPLGPLATTSHRGABRP | |
| SCHEMBL28587488 | 0.81 | LMNA (0.40) | LMNAPLGPLATTSHRGABRP | |
| SCHEMBL28596169 | 0.81 | LMNA (0.40) | LMNAPLGPLATTSHRGABRP | |
| Cyclopropane Carboxylic Acid SCHEMBL27948176 | 0.79 | — | — | |
| Propene SCHEMBL11667894 | 0.79 | LMNA (0.46) | LMNAPLGPLATTSHRGABRP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219492-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-3790877-B1 | TETRAHYDRO-IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS PD-L1 IMMUNOMODULATORS | INCYTE CORP (US) | 2023-03-01 | — | — | EP | disclosed |
| US-20220348594-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2022-11-03 | — | — | US | disclosed |
| US-11414433-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2022-08-16 | — | — | US | disclosed |
| US-20210115068-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2021-04-22 | — | — | US | disclosed |
| EP-3790877-A1 | TETRAHYDRO-IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS PD-L1 IMMUNOMODULATORS | Incyte Corporation (US) | 2021-03-17 | — | — | EP | disclosed |
| US-10906920-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2021-02-02 | — | — | US | disclosed |
| US-20200277309-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2020-09-03 | — | — | US | disclosed |
| US-10618916-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2020-04-14 | — | — | US | disclosed |
| US-20190345170-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2019-11-14 | — | — | US | disclosed |
| WO-2019217821-A1 | TETRAHYDRO-IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS PD-L1 IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2019-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10906920-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | LMNA 4857/4885PLG 4258/4885PLAT 4214/4885 |
| US-20210115068-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | LMNA 4857/4885PLG 4258/4885PLAT 4214/4885 |
| US-10618916-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | LMNA 4857/4885PLG 4258/4885PLAT 4214/4885 |
| US-11414433-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | LMNA 4857/4885PLG 4258/4885PLAT 4214/4885 |
| US-20200277309-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | LMNA 4857/4885PLG 4258/4885PLAT 4214/4885 |
| US-20220348594-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | LMNA 4857/4885PLG 4258/4885PLAT 4214/4885 |
| US-20190345170-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | LMNA 4857/4885PLG 4258/4885PLAT 4214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.